Infections pose a severe global health threat, with 14 billion cases annually and 11 million fatalities attributed to sepsis. Hospitals worldwide face a significant challenge, as 40% of ICU deaths result from undiagnosed infections due to limited diagnostic capabilities, making patients reliant on symptom-based therapy.

The infexn^TM test by HaystackAnalytics, is a groundbreaking genomics solution that utilizes advanced data analytics for rapid and precise detection of infectious diseases. This 'Made in India' proprietary technology can detect all bacteria and fungi while simultaneously identifying major antimicrobial resistance genes. With a remarkable 12-hour turnaround time and direct sample analysis, it surpasses the limitations of traditional microbial cultures, providing clinicians with comprehensive and evidence-based diagnostic insights.

HaystackAnalytics addresses the global health threat of infections with its infexn^TM test, leveraging genome sequencing for rapid pathogen and antimicrobial profile detection within 12 hours. This innovative solution ensures timely treatment, critical for saving lives, particularly in the context of drug-resistant pathogens. Their unique proposition lies in a genomic Single Test Solution, providing accessible clinical therapy within a 12-hour turnaround time. The infexn^TM test's genomic approach enhances pathogen identification, even for rare and challenging infections.

Over the next 3-5 years, their growth strategy involves widespread access to genomics by collaborating with numerous labs and hospitals. The plan includes expanding their product range in Southeast Asia and the Middle East by 2024, with subsequent expansion into the US and Europe.